MiMedx Group Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good morning, and thanks for joining us to have a conversation with Tim Wright, CEO; and Bob Stein, Executive Vice President, R&D of MiMedx. MiMedx is a leader in wound care and regenerative medicine. The company currently commercializes a portfolio of amniotic tissue products, bringing in nearly $250 million in annual revenues and has a portfolio of products for novel indications that could enter the market over the next 3 years.
To talk about the company's strategy for 2022 and beyond, I welcome Tim Wright and Bob Stein to this fireside chat with me. Tim and Bob, glad to see you both, and I appreciate you accepting our invitation to talk to our audience today.
Questions & Answers
So let us start talking through some of your thoughts on the commercial growth in 2022 and then about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
